Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4536.T Stock Summary
Top 10 Correlated ETFs
4536.T
In the News
4536.T Financial details
Company Rating
Strong Buy
Market Cap
535.9B
Income
27.73B
Revenue
302.08B
Book val./share
844.74
Cash/share
235.72
Dividend
32
Dividend %
2.17%
Employees
4.14K
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
20.15
Forward P/E
16.32
PEG
17.79
P/S
1.83
P/B
1.73
P/C
6.34
P/FCF
16.55
Quick Ratio
1.97
Current Ratio
2.66
Debt / Equity
0.11
LT Debt / Equity
0.11
-
-
EPS (TTM)
75.78
EPS next Y
91.59
EPS next Q
13.64
EPS this Y
-156.68%
EPS next Y
20.87%
EPS next 5Y
37.88%
EPS last 5Y
NAN%
Revenue last 5Y
3.58%
Revenue Q/Q
4.92%
EPS Q/Q
-15.77%
-
-
-
-
SMA20
-4.26%
SMA50
1.19%
SMA100
14.13%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
9%
ROC
0.12%
Gross Margin
61%
Oper. Margin
14%
Profit Margin
9%
Payout
46%
Shs Outstand
363.2M
Shs Float
312.89M
-
-
-
-
Target Price
-
52W Range
1060.0-1589.5
52W High
-5.92%
52W Low
+41.04%
RSI
55.47
Rel Volume
0.6
Avg Volume
1.26M
Volume
756.3K
Perf Week
3.32%
Perf Month
-3.98%
Perf Quarter
7.98%
Perf Half Y
5.24%
-
-
-
-
Beta
0.262
-
-
Volatility
17.46%, 40.69%
Prev Close
-0.8%
Price
1495
Change
-1.25%
4536.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 576.18 | 605.16 | 624.86 | 666.02 | 720.24 | |
Net income per share | 78.64 | 59.17 | 17.1 | 68.08 | -38.58 | |
Operating cash flow per share | 80.99 | 100.08 | 97.15 | 115.17 | 95.88 | |
Free cash flow per share | 60.47 | 76.96 | 37.56 | 25.52 | 32.42 | |
Cash per share | 174.96 | 230.19 | 158.75 | 210.89 | 151.46 | |
Book value per share | 716.21 | 758.76 | 770.01 | 844.19 | 758.81 | |
Tangible book value per share | 341.61 | 402.31 | 418.86 | 482.55 | 489.4 | |
Share holders equity per share | 716.21 | 758.76 | 770.01 | 844.19 | 758.81 | |
Interest debt per share | 17.1 | 25.26 | 17.02 | 69.67 | 84.54 | |
Market cap | 679.92B | 741.63B | 608.37B | 490.52B | 437.78B | |
Enterprise value | 613.19B | 662.53B | 555.63B | 440.44B | 416.09B | |
P/E ratio | 21.29 | 31.4 | 89.07 | 18.02 | -29.29 | |
Price to sales ratio | 2.91 | 3.07 | 2.44 | 1.84 | 1.57 | |
POCF ratio | 20.67 | 18.57 | 15.68 | 10.65 | 11.79 | |
PFCF ratio | 27.68 | 24.14 | 40.55 | 48.08 | 34.86 | |
P/B Ratio | 2.34 | 2.45 | 1.98 | 1.45 | 1.49 | |
PTB ratio | 2.34 | 2.45 | 1.98 | 1.45 | 1.49 | |
EV to sales | 2.62 | 2.74 | 2.23 | 1.65 | 1.49 | |
Enterprise value over EBITDA | 10.76 | 12.98 | 18.11 | 8.17 | 32.13 | |
EV to operating cash flow | 18.64 | 16.59 | 14.32 | 9.57 | 11.2 | |
EV to free cash flow | 24.97 | 21.57 | 37.03 | 43.17 | 33.13 | |
Earnings yield | 0.05 | 0.03 | 0.01 | 0.06 | -0.03 | |
Free cash flow yield | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | |
Debt to equity | 0.01 | 0.03 | 0.02 | 0.08 | 0.11 | |
Debt to assets | 0.01 | 0.02 | 0.01 | 0.06 | 0.07 | |
Net debt to EBITDA | -1.17 | -1.55 | -1.72 | -0.93 | -1.68 | |
Current ratio | 3.21 | 3.23 | 2.63 | 2.39 | 2.38 | |
Interest coverage | 15.65 | 14.01 | 8.68 | 29.68 | -2.06 | |
Income quality | 1.03 | 1.84 | 5.84 | 1.69 | -2.48 | |
Dividend Yield | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | |
Payout ratio | 0.33 | 0.44 | 1.64 | 0.44 | -0.84 | |
Sales general and administrative to revenue | 0.3 | 0.3 | 0.32 | 0.32 | 0.34 | |
Research and developement to revenue | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
Intangibles to total assets | 0.34 | 0.29 | 0.28 | 0.28 | 0.23 | |
Capex to operating cash flow | -0.25 | -0.23 | -0.61 | -0.78 | -0.66 | |
Capex to revenue | -0.04 | -0.04 | -0.1 | -0.13 | -0.09 | |
Capex to depreciation | -0.76 | -0.56 | -1.42 | -2.1 | -1.43 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.13K | 1.01K | 544.27 | 1.14K | 811.63 | |
ROIC | 0.11 | 0.07 | 0.02 | 0.07 | -0.02 | |
Return on tangible assets | 0.12 | 0.08 | 0.02 | 0.08 | -0.05 | |
Graham Net | 131.79 | 171.77 | 152.44 | 136.17 | 79.73 | |
Working capital | 134.08B | 150.96B | 127.68B | 133.61B | 123.82B | |
Tangible asset value | 161.46B | 182.71B | 194.17B | 206.63B | 196.99B | |
Net current asset value | 96.13B | 112.35B | 110.93B | 106.29B | 85.44B | |
Invested capital | 0.01 | 0.03 | 0.02 | 0.08 | 0.11 | |
Average receivables | 81.64B | 85.81B | 91.5B | 97.79B | 103.41B | |
Average payables | 30.91B | 32.33B | 35.34B | 39.65B | 43.07B | |
Average inventory | 32.94B | 35.26B | 38.43B | 39.36B | 38.25B | |
Days sales outstanding | 131.97 | 131.46 | 140.37 | 136.52 | 140.26 | |
Days payables outstanding | 129 | 125.39 | 141.61 | 137.07 | 145.24 | |
Days of inventory on hand | 141.69 | 135.8 | 154.5 | 123.61 | 127.17 | |
Receivables turnover | 2.77 | 2.78 | 2.6 | 2.67 | 2.6 | |
Payables turnover | 2.83 | 2.91 | 2.58 | 2.66 | 2.51 | |
Inventory turnover | 2.58 | 2.69 | 2.36 | 2.95 | 2.87 | |
ROE | 0.11 | 0.08 | 0.02 | 0.08 | -0.05 | |
Capex per share | -20.52 | -23.12 | -59.59 | -89.65 | -63.47 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 183.83 | 210.2 | 194.19 | 203.68 | 217.82 | |
Net income per share | 15.5 | 2.96 | 27.94 | 24.6 | 20.73 | |
Operating cash flow per share | 26.32 | 22.99 | 6.82 | 69.88 | 89.67 | |
Free cash flow per share | 14.04 | 12.57 | -1.05 | 63.61 | 85.07 | |
Cash per share | 161.65 | 155.63 | 126.33 | 184.1 | 235.72 | |
Book value per share | 780.57 | 779.73 | 807.25 | 852.23 | 844.74 | |
Tangible book value per share | 517.88 | 502.89 | 544.92 | 587.1 | 584.02 | |
Share holders equity per share | 780.57 | 779.73 | 807.25 | 852.23 | 844.74 | |
Interest debt per share | 99.14 | 84.99 | 93.51 | 95.4 | 97.07 | |
Market cap | 414.05B | 426.04B | 456.84B | 495.08B | 496.84B | |
Enterprise value | 389.92B | 404.34B | 446.02B | 464.26B | 448.44B | |
P/E ratio | 17.32 | 95.44 | 10.97 | 13.96 | 16.94 | |
Price to sales ratio | 5.84 | 5.38 | 6.31 | 6.74 | 6.45 | |
POCF ratio | 40.8 | 49.16 | 179.58 | 19.66 | 15.67 | |
PFCF ratio | 76.51 | 89.9 | -1.16K | 21.59 | 16.52 | |
P/B Ratio | 1.38 | 1.45 | 1.52 | 1.61 | 1.66 | |
PTB ratio | 1.38 | 1.45 | 1.52 | 1.61 | 1.66 | |
EV to sales | 5.5 | 5.1 | 6.16 | 6.32 | 5.82 | |
Enterprise value over EBITDA | 30.56 | 37.83 | 26.13 | 27.98 | 30.15 | |
EV to operating cash flow | 38.42 | 46.65 | 175.32 | 18.43 | 14.14 | |
EV to free cash flow | 72.05 | 85.32 | -1.13K | 20.25 | 14.91 | |
Earnings yield | 0.01 | 0 | 0.02 | 0.02 | 0.01 | |
Free cash flow yield | 0.01 | 0.01 | 0 | 0.05 | 0.06 | |
Debt to equity | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | |
Debt to assets | 0.09 | 0.07 | 0.08 | 0.08 | 0.08 | |
Net debt to EBITDA | -1.89 | -2.03 | -0.63 | -1.86 | -3.25 | |
Current ratio | 2.73 | 2.38 | 2.67 | 2.66 | 2.46 | |
Interest coverage | 7.89 | 8.93 | 75.89 | 25.41 | 15.73 | |
Income quality | 1.71 | 7.84 | 0.24 | 2.84 | 4.34 | |
Dividend Yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
Payout ratio | 1.02 | 0.09 | 0.57 | 0.01 | 0.79 | |
Sales general and administrative to revenue | 0.33 | 0.39 | 0.29 | 0.3 | 0.28 | |
Research and developement to revenue | 0.1 | 0.08 | 0.09 | 0.08 | 0.07 | |
Intangibles to total assets | 0.24 | 0.23 | 0.23 | 0.22 | 0.21 | |
Capex to operating cash flow | -0.47 | -0.45 | -1.15 | -0.09 | -0.05 | |
Capex to revenue | -0.07 | -0.05 | -0.04 | -0.03 | -0.02 | |
Capex to depreciation | -1.15 | -0.96 | -0.73 | -0.46 | -0.35 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 521.81 | 227.88 | 712.32 | 686.77 | 627.76 | |
ROIC | 0.02 | 0 | 0.03 | 0.03 | 0.03 | |
Return on tangible assets | 0.02 | 0 | 0.03 | 0.03 | 0.02 | |
Graham Net | 84.55 | 81.93 | 79.87 | 107.44 | 115.06 | |
Working capital | 129.85B | 123.82B | 127.07B | 134.89B | 133.17B | |
Tangible asset value | 199.65B | 196.99B | 203.14B | 211.62B | 206.52B | |
Net current asset value | 84.91B | 85.44B | 86.96B | 95.45B | 94.77B | |
Invested capital | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | |
Average receivables | 91.51B | 101.28B | 105.53B | 98.66B | 89.21B | |
Average payables | 39.38B | 43.27B | 43.14B | 42.6B | 44.5B | |
Average inventory | 38.21B | 38.33B | 40.79B | 43.9B | 46.25B | |
Days sales outstanding | 121.07 | 121.77 | 129.09 | 114.6 | 99.25 | |
Days payables outstanding | 126.68 | 147.09 | 123.89 | 134.18 | 126.33 | |
Days of inventory on hand | 113.64 | 128.78 | 126.58 | 139.35 | 131.38 | |
Receivables turnover | 0.74 | 0.74 | 0.7 | 0.79 | 0.91 | |
Payables turnover | 0.71 | 0.61 | 0.73 | 0.67 | 0.71 | |
Inventory turnover | 0.79 | 0.7 | 0.71 | 0.65 | 0.69 | |
ROE | 0.02 | 0 | 0.03 | 0.03 | 0.02 | |
Capex per share | -12.28 | -10.42 | -7.88 | -6.26 | -4.59 |
4536.T Frequently Asked Questions
What is Santen Pharmaceutical Co., Ltd. stock symbol ?
Santen Pharmaceutical Co., Ltd. is a JP stock and trading under the symbol 4536.T
What is Santen Pharmaceutical Co., Ltd. stock quote today ?
Santen Pharmaceutical Co., Ltd. stock price is $1495 today.
Is Santen Pharmaceutical Co., Ltd. stock public?
Yes, Santen Pharmaceutical Co., Ltd. is a publicly traded company.